Invalidity dossier
US 6193985
Added 9/23/2026, 7:46:41 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 6,193,985 B1
Title: Tocopherol compositions for delivery of biologically active agents
Patent number: US 6,193,985 B1 (application US 08/856,054)
Inventor: Mette Rydahl Sonne
Original assignee: Dumex AS. The listed current assignee is Actavis Group hf; the source notes assignees "may be inaccurate."
Key dates (as listed): Priority date 1994-05-16; filing date 1997-05-14; publication/grant 2001-02-27; anticipated expiration 2015-05-16. Legal status: expired – lifetime.
Purpose and plain-language scope (based only on the supplied excerpt):
The patent concerns compositions in which tocopherol (including α-tocopherol and tocopherol derivatives such as tocophersolan) serves as a vehicle or delivery medium for biologically active agents. The excerpt's keyword and classification data indicate the compositions may take the form of emulsions and may include water, solvents, emulsifying agents/surface-active agents, and polymers or bioadhesive materials, with applications including oral/mouth and topical delivery.
Biologically active agents named in the excerpt include diazepam, midazolam, temazepam, lorazepam, alprazolam, brotizolam, and benzodiazepines generally; disulfiram; miconazole, ketoconazole, and other antimycotics; cinnarizine, verapamile, metoclopramide, lidocaine, morphine, indomethacin, ibuprofen, erythromycin, tetracyclines, metronidazole, tinidazole, aciclovir, idoxuridine, griseofulvin, amphotericin-B, cyclosporins, nitroglycerin, nicotinic acid/niacin, linoleate, and vitamin K derivatives, among others. Indications mentioned include motion sickness and migraine.
The excerpt indicates 99 claims, with "composition" and "tocopherol" as leading prior-art keywords.
Source: https://patents.google.com/patent/US6193985/en
What the excerpt does not establish: It does not set out the actual claim language, the written description, examples or dosages, or the specific prior-art references cited. It does not establish inventorship disputes, validity, infringement, or the accuracy of the listed assignees or legal status. No litigation or ownership-transfer conclusions are drawn here.
Generated 10/1/2026, 9:41:49 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 6193985. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.